SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X]

Filed by a party other than the Registrant [  ]

Check the appropriate box:

[   ]
[   ]
[X]
[   ]
[   ] Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to ss. 240.14a-11(c) or ss. 240.14a-12

The Immune Response Corporation (Name of Registrant as Specified In Its Charter)

N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]  No fee required

[   ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1)     Title of each class of securities to which transaction applies:

2)      Aggregate number of securities to which transaction applies:

3)      Per unit price or other underlying value of transaction computed pursuant to Exchange Act
     Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
      determined):

4)      Proposed maximum aggregate value of transaction:

5)      Total fee paid:

[   ] Fee paid previously with preliminary materials.

[   ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1)      Amount Previously Paid:

2)       Form, Schedule or Registration Statement No.:

3)      Filing Party:

4)      Date Filed: October 17, 2002

EXPLANATORY NOTE

         In the revised Proxy Statement of The Immune Response Corporation (the “Company”) filed with the Securities and Exchange Commission on October 8, 2002, there was an error in the 10-Year Option Repricings table that has now been corrected, as reflected below. The error appeared in the Date of Repricing column. The table indicates that the date of each repricing was 9/30/2002. The actual date of the repricing was 8/30/2002. There are no other revisions, corrections or amendments to the Company’s revised Proxy Statement filed on October 8, 2002.

10-Year Option Repricings

Name	Date of Repricing	Number of Securities Underlying Options Repriced	Market Price of Stock at Time of Repricing	Exercise Price at Time of Repricing	New Exercise Price	Length of Original Option Term Remaining at Date of Repricing
Dennis J. Carlo	8/30/2002	6,498	$0.54	$3.25	$0.54	31 Months
	8/30/2002	5,258	$0.54	$3.13	$0.54	32 Months
	8/30/2002	7,896	$0.54	$6.56	$0.54	41 Months
	8/30/2002	3,810	$0.54	$7.75	$0.54	46 Months
	8/30/2002	3,052	$0.54	$8.19	$0.54	52 Months
	8/30/2002	2,487	$0.54	$10.06	$0.54	63 Months
	8/30/2002	12,512	$0.54	$10.06	$0.54	64 Months
	8/30/2002	1,414	$0.54	$8.875	$0.54	75 Months
	8/30/2002	4,077	$0.54	$7.063	$0.54	86 Months
	8/30/2002	8,024	$0.54	$5.938	$0.54	95 Months
	8/30/2002	38,517	$0.54	$5.938	$0.54	97 Months
	8/30/2002	—	$0.54	$3.938	$0.54	103 Months

         In connection with Dr. Carlo’s resignation as our President and Chief Executive Officer, we entered into with Dr. Carlo an Employment Agreement and General Release which provided for, among other things, the repricing of 97,762 options previously granted to Dr. Carlo. Each of the stock options affected by this repricing will vest on the date which is six (6) months after Dr. Carlo ceases to provide continuous service to the Company (either as an employee or a consultant). All other provisions of the repriced stock options are to remain the same.

-----END PRIVACY-ENHANCED MESSAGE-----